Parabilis Medicines, Inc. balance sheet PBLS

As of Jun 30, 2026, Parabilis Medicines, Inc. had total assets of $1.2 billion and total liabilities of $127.5 million. Stockholders' equity was $1.0 billion. It held $1.1 billion in cash and investments against $53.2 million of total debt, net cash of $1.1 billion. The current ratio, current assets divided by current liabilities, was 17.91.

USD in millions, except ratios and per-share amounts. The percent under a figure is the change from the same quarter a year earlier.

Line
Q2 FY2026
Jun 30, 2026
Assets
Cash
1,087
Short-term investments
34
Cash and investments
1,121
Total current assets
1,125
Property and equipment, net
7
Total assets
1,175
Liabilities and equity
Accounts payable
19
Total current liabilities
63
Total liabilities
128
Stockholders' equity
1,048
Debt
Debt due within a year
11
Long-term debt
1
Lease liabilities
42
Total debt
53
Net cash
1,067
Ratios
Current ratio
17.91x
Debt to equity
0.05x
Book value per share
8.59
How these figures are calculated

Quarterly columns are single-quarter amounts. When a 10-Q reports only a year-to-date total, as cash flow statements do, the quarter is that total minus the previous quarter's year-to-date total. The fourth quarter is the annual report's full year minus the first nine months. A column marked YTD is a year-to-date total, shown when the earlier report needed for the single quarter is missing. USD in millions, except ratios and per-share amounts. Cash and investments adds short-term and long-term marketable securities to cash. Debt due within a year is the borrowings that are not already in long-term debt. Total debt is those borrowings plus lease liabilities. Net cash is cash and investments minus total debt. Return on equity and return on assets divide the trailing twelve months of net income by the balance on that date. Debt to EBITDA uses the trailing twelve months of EBITDA. More on our methodology.

Company profile

Industry
Pharmaceutical Preparations (SIC 2834)
Listed as
PBLS (Nasdaq)
Fiscal year ends
December 31
Incorporated in
DE
Headquarters
Cambridge, MA
SEC filer status
, Emerging growth company
SEC CIK
1657677
Former names
FOG PHARMACEUTICALS, INC. (until Dec 2, 2022)

Other Pharmaceutical Preparations companies

Source: SEC EDGAR filings. This is company-reported data, not investment advice.